VALNEVA SE (VLA.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:VLA • FR0004056851

4.03 EUR
+0 (+0.05%)
Last: Feb 9, 2026, 09:36 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

2

Taking everything into account, VLA scores 2 out of 10 in our fundamental rating. VLA was compared to 81 industry peers in the Biotechnology industry. Both the profitability and financial health of VLA have multiple concerns. VLA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year VLA has reported negative net income.
  • In the past year VLA has reported a negative cash flow from operations.
  • VLA had negative earnings in each of the past 5 years.
  • In multiple years VLA reported negative operating cash flow during the last 5 years.
VLA.PA Yearly Net Income VS EBIT VS OCF VS FCFVLA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

  • With a Return On Assets value of -26.86%, VLA perfoms like the industry average, outperforming 53.09% of the companies in the same industry.
  • The Return On Equity of VLA (-80.02%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -26.86%
ROE -80.02%
ROIC N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
VLA.PA Yearly ROA, ROE, ROICVLA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • Looking at the Gross Margin, with a value of 46.53%, VLA is in line with its industry, outperforming 43.21% of the companies in the same industry.
  • In the last couple of years the Gross Margin of VLA has declined.
  • VLA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
VLA.PA Yearly Profit, Operating, Gross MarginsVLA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, VLA has more shares outstanding
  • VLA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, VLA has an improved debt to assets ratio.
VLA.PA Yearly Shares OutstandingVLA.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
VLA.PA Yearly Total Debt VS Total AssetsVLA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of -0.76, we must say that VLA is in the distress zone and has some risk of bankruptcy.
  • VLA has a Altman-Z score (-0.76) which is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.89 indicates that VLA is somewhat dependend on debt financing.
  • VLA's Debt to Equity ratio of 0.89 is in line compared to the rest of the industry. VLA outperforms 41.98% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Altman-Z -0.76
ROIC/WACCN/A
WACC7.9%
VLA.PA Yearly LT Debt VS Equity VS FCFVLA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • VLA has a Current Ratio of 1.78. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
  • VLA has a Current ratio (1.78) which is in line with its industry peers.
  • VLA has a Quick Ratio of 1.36. This is a normal value and indicates that VLA is financially healthy and should not expect problems in meeting its short term obligations.
  • VLA has a Quick ratio (1.36) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.36
VLA.PA Yearly Current Assets VS Current LiabilitesVLA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • VLA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1180.00%.
  • VLA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.89%.
  • Measured over the past years, VLA shows a small growth in Revenue. The Revenue has been growing by 6.09% on average per year.
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
Revenue 1Y (TTM)19.89%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%

3.2 Future

  • The Earnings Per Share is expected to grow by 55.11% on average over the next years. This is a very strong growth
  • VLA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.00% yearly.
EPS Next Y-607%
EPS Next 2Y-121.49%
EPS Next 3Y101.1%
EPS Next 5Y55.11%
Revenue Next Year-6.69%
Revenue Next 2Y2.34%
Revenue Next 3Y27.3%
Revenue Next 5Y17%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VLA.PA Yearly Revenue VS EstimatesVLA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
VLA.PA Yearly EPS VS EstimatesVLA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VLA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VLA.PA Price Earnings VS Forward Price EarningsVLA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VLA.PA Per share dataVLA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • VLA's earnings are expected to grow with 101.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-121.49%
EPS Next 3Y101.1%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for VLA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VALNEVA SE

EPA:VLA (2/9/2026, 9:36:06 AM)

4.03

+0 (+0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)02-19
Inst Owners24.02%
Inst Owner ChangeN/A
Ins Owners0.21%
Ins Owner ChangeN/A
Market Cap349.43M
Revenue(TTM)274.97M
Net Income(TTM)-120.41M
Analysts81.82
Price Target7.28 (80.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17%
Min EPS beat(2)-90.69%
Max EPS beat(2)56.68%
EPS beat(4)2
Avg EPS beat(4)-21.59%
Min EPS beat(4)-115.24%
Max EPS beat(4)62.87%
EPS beat(8)4
Avg EPS beat(8)-5.97%
EPS beat(12)6
Avg EPS beat(12)-29.73%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.23%
Min Revenue beat(2)-26.86%
Max Revenue beat(2)16.4%
Revenue beat(4)2
Avg Revenue beat(4)2.94%
Min Revenue beat(4)-26.86%
Max Revenue beat(4)26.97%
Revenue beat(8)3
Avg Revenue beat(8)-2.55%
Revenue beat(12)7
Avg Revenue beat(12)17.96%
Revenue beat(16)9
Avg Revenue beat(16)99.55%
PT rev (1m)8.53%
PT rev (3m)1.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.69%
EPS NY rev (1m)7.55%
EPS NY rev (3m)1.72%
Revenue NQ rev (1m)-8.1%
Revenue NQ rev (3m)-12.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.27
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB 2.74
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS3.17
BVpS1.74
TBVpS1.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -26.86%
ROE -80.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.53%
FCFM N/A
ROA(3y)-15.85%
ROA(5y)-14.17%
ROE(3y)-50.34%
ROE(5y)-55.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.2%
GM growth 5Y-7.06%
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.08%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.36
Altman-Z -0.76
F-Score4
WACC7.9%
ROIC/WACCN/A
Cap/Depr(3y)101.58%
Cap/Depr(5y)231.17%
Cap/Sales(3y)9.04%
Cap/Sales(5y)14.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1180%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-271.43%
EPS Next Y-607%
EPS Next 2Y-121.49%
EPS Next 3Y101.1%
EPS Next 5Y55.11%
Revenue 1Y (TTM)19.89%
Revenue growth 3Y-21.31%
Revenue growth 5Y6.09%
Sales Q2Q%-35.76%
Revenue Next Year-6.69%
Revenue Next 2Y2.34%
Revenue Next 3Y27.3%
Revenue Next 5Y17%
EBIT growth 1Y-162.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-269.56%
EBIT Next 3Y56.42%
EBIT Next 5Y30.38%
FCF growth 1Y91.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y90.46%
OCF growth 3YN/A
OCF growth 5YN/A

VALNEVA SE / VLA.PA FAQ

Can you provide the ChartMill fundamental rating for VALNEVA SE?

ChartMill assigns a fundamental rating of 2 / 10 to VLA.PA.


Can you provide the valuation status for VALNEVA SE?

ChartMill assigns a valuation rating of 1 / 10 to VALNEVA SE (VLA.PA). This can be considered as Overvalued.


Can you provide the profitability details for VALNEVA SE?

VALNEVA SE (VLA.PA) has a profitability rating of 1 / 10.


How financially healthy is VALNEVA SE?

The financial health rating of VALNEVA SE (VLA.PA) is 3 / 10.